Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Thalidomide + Dexamethasone vs Thalidomide + Dexamethasone in relapsed multiple myeloma after autologous transplant
2005-001628-35Phase 3Completed
- Sponsor
- EBMT
- Start
- Dec 2005
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by EBMT. Primary endpoint: Time to progression. Started Dec 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-001628-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001628-35.